Fundraising Fox
Chemomab
Tel Aviv · Founded 2011 · 20 employees on LinkedIn · 3 known investors
Find your way into Chemomab
Sign up to see every warm intro you have to Chemomab
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Chemomab team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis. The company focuses on anti-fibrotic and anti-inflammatory treatments for patients with fibrotic diseases.
Founders & leadership
Chemomab was founded in 2011 by Adi Mor and Adi Mor George.
AM
Adi Mor GeorgeCo-founder
JQ
Jill QuigleyMember of the Board of Directors2022–2026Jill Quigley is Director at Chemomab, a clinical-stage biotech developing therapies targeting fibro-inflammatory diseases. She previously held leadership roles at Passage Bio, Terns Pharmaceuticals, Genuiti Therapeutics, and earlier-stage biotech companies, with experience in capital raising, corporate strategy, and M&A transactions.
MF
Matthew FrankelChief Medical Officer (CMO)2022–2025Matthew Frankel is a physician with over two decades of clinical development and medical affairs experience across biotechnology and pharmaceutical organizations, including prior roles as Chief Medical Officer at Chemomab and Boehringer Ingelheim, VP of immunology and dermatology at Novartis, and leadership positions at FibroGen, Reata, Sandoz, Abbott, and Schering-Plough; he holds an M.D. from UCLA, an MBA from Northwestern's Kellogg School, and a B.A. from Vassar College.
AA
Arnon AharonChief Medical Officer2016–2022A physician and biotech executive with over 20 years of leadership experience, Arnon Aharon has held senior roles at public and private life-science companies including Clal Biotechnology Industries, ChemomAb Therapeutics, BioLineRx, and Pharmos, working across therapeutic development from preclinical research through Phase III clinical trials. He has co-founded multiple biotech ventures and serves as a member of investment and evaluation committees at the Weizmann Institute of Science and Berlin Institute of Health.
SF
Sigal FatalExecutive
Board
ND
Nissim DarvishBoard directorExecutive Officer at OrbiMed
SP
NH
AC
Alan Charles MosesBoard director
CN
Claude NicaiseBoard director
Investors · 3
Altium Capitallisted by Altium CapitalNew York
How we know: Altium Capital's portfolio page · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$55.4M disclosed across 2 of 3 rounds · 2021–2026
▶$10MraisedAug 2024 · 10 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neil Harris CohenDirector
- Jill QuigleyDirector
- Sigal FattalExecutive Officer
- Adi MorExecutive Officer, Director
- Alan Charles MosesDirector
- Matthew FrankelExecutive Officer
- Claude NicaiseDirector
- Nissim DarvishDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $400K
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Jul 2024
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$45.4MraisedMar 2021 · 26 investors · BiotechnologyRule 506(b)
▶$45.4MraisedMar 2021 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adi Mor GeorgeExecutive Officer, Director
- Arnon AharonExecutive Officer
- Neil Harris CohenDirector
- Joel Michael MarylesDirector
- Nissim DarvishDirector
- Claude NicaiseDirector
- Sigal FatalExecutive Officer
- Stephen P SquintoDirector
- Moses Charles AlanDirector
- Offering amount
- $45.4M
- Amount sold
- $45.4M
- Sales commissions
- $1.6M
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Mar 2021
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Chemomab do?
- Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis. The company focuses on anti-fibrotic and anti-inflammatory treatments for patients with fibrotic diseases.
- Who founded Chemomab?
- Chemomab was founded by Adi Mor, Adi Mor George in 2011.
- Who are Chemomab's investors?
- Chemomab's investors include Altium Capital, OrbiMed, SBI JI Innovation Advisory Ltd..
- How much funding has Chemomab raised?
- Chemomab has disclosed $55.4M raised across 2 of its 3 known rounds.
- Where is Chemomab headquartered?
- Chemomab is headquartered in Tel Aviv.